Validation of a 3D perfused cell culture platform as a tool for humanised preclinical drug testing in breast cancer using established cell lines and patient-derived tissues
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0283044 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Peng Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Centre for the Replacement, Refinement and Reduction of Animals in Research, Cancer Research UK, University of Aberdeen.
Abstract (Originalsprache)
3D cell culture models of cancer are currently being developed to recapitulate in vivo physiological conditions and to assess therapeutic responses. However, most models failed to incorporate the biochemical and biophysical stimuli from fluid flow. In this study, a three-dimensional scaffold, SeedEZ was applied within the PerfusionPal perfused culture system to investigate how perfusion, and blood-like oxygen delivery influenced breast cancer cell growth and their responses to a commonly used breast cancer drug tamoxifen. Our results showed that breast cancer cells could be maintained over 3 weeks in PerfusionPal with increased cell viability compared to static 3D culture in fully humanised conditions. This platform also supported examining the effect of tamoxifen on breast cancer cell lines and in primary patient-derived breast cancer samples. Future work is warranted to further the adaption for fully humanised assessment of drug effectiveness in a patient personalized approach with the aim to reduce the burden of animal use in cancer research and increase the degree of human pre-clinical data translation to clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom.
- Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom.
- Lena Biosciences, Atlanta, GA, United States of America.
- School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom.
ORCID-Profile: Peng Liu
Förderung
- National Centre for the Replacement, Refinement and Reduction of Animals in Research
- Cancer Research UK
- University of Aberdeen
Zitieren
APA
Liu, P., Roberts, S., Shoemaker, J. T., Vukasinovic, J., Tomlinson, D. C., & Speirs, V. (2023). Validation of a 3D perfused cell culture platform as a tool for humanised preclinical drug testing in breast cancer using established cell lines and patient-derived tissues. PLOS ONE. https://doi.org/10.1371/journal.pone.0283044
Vancouver
Liu P, Roberts S, Shoemaker JT, Vukasinovic J, Tomlinson DC, Speirs V. Validation of a 3D perfused cell culture platform as a tool for humanised preclinical drug testing in breast cancer using established cell lines and patient-derived tissues. PLOS ONE. 2023. doi:10.1371/journal.pone.0283044
BibTeX
@article{Liu2023,
author = {Liu, Peng and Roberts, Sophie and Shoemaker, James T and Vukasinovic, Jelena and Tomlinson, Darren C and Speirs, Valerie},
title = {Validation of a 3D perfused cell culture platform as a tool for humanised preclinical drug testing in breast cancer using established cell lines and patient-derived tissues},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0283044}
}
EUVIMED